Skip to content



Polio Highlight

Background and Technical Rationale for Introduction of one dose of Inactivated Polio Vaccine (IPV) in Routine Immunization Schedule

A handbook for training regional consultants and briefing NITAG members on technical aspects related to introduction of IPV as it relates to the Polio Eradication and Endgame Strategic Plan.

icon Background and Technical Rationale for Introduction of one dose of Inactivated Polio Vaccine (IPV) in Routine Immunization Schedule 

Brief on IPV Introduction, OPV Withdrawal, and Routine Immunization Strengthening

This document outlines steps for IPV Introduction, OPV Withdrawal, and Routine Immunization Strengthening

icon Brief on IPV Introduction, OPV Withdrawal, and Routine Immunization Strengthening

Looking Forward into 2015

The GPEI sets priorities to make 2015 the last stand of the poliovirus around the world

The last few years have seen the Global Polio Eradication Initiative (GPEI) evolve and grow in response to the threats posed to the world by the final strongholds of the poliovirus. Despite being more geographically limited than ever before, at the end of 2014 the virus continues to pose challenges that must be faced in 2015 if we are to protect children from this disease forever. Polio eradication efforts in 2015 will have five priorities: refining surveillance to catch any remaining virus, keeping Africa and the Middle East polio-free, providing a surge of support to Pakistan and Afghanistan, preparing for the withdrawal of oral polio vaccine type 2 and continuing to demonstrate and build on the differences that the polio programme makes to strengthen routine immunization programmes.

Read more here

IPV in 5 doses vial was prequalified by WHO and approved to be used up to 28 days

IPV in 5 dose vials, produced by Bilthoven Biologicals, was recently prequalified and approved for use up to 28 days after opening if the following additional criteria, defined by the WHO, are fully met.

1.     The expiration date of the vaccine has not passed.

2.     The vaccine vial has been, and will continue to be, stored at WHO- or manufacturer-recommended temperatures.

For further details on the handling of multi-dose vaccine vials after opening, follow the link for WHO Policy Statement: Multi-dose Vial Policy, Revision 2014: bit.ly/PolioHL14-48
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 2 of 30

Regional Office for the Americas of the World Health Organization
525 Twenty-third Street, N.W., Washington, D.C. 20037, United States of America
Tel.: +1 (202) 974-3000 Fax: +1 (202) 974-3663

© Pan American Health Organization. All rights reserved.